Volume Replacement Strategies Do Not Impair the Binding of Dabigatran to Idarucizumab: Porcine Model of Hemodilution

PLoS ONE - United States
doi 10.1371/journal.pone.0209350
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Efficacy of Idarucizumab, Prothrombin Complex Concentrate (PCC) and Activated PCC to Reverse the Anticoagulatory Potential of Dabigatran in a Porcine Polytrauma Model

Critical Care
Critical CareIntensive Care Medicine
2015English

Idarucizumab for the Reversal of Dabigatran in Patients Undergoing Heart Transplantation

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

Idarucizumab Resistance Due to a Markedly Elevated Dabigatran Concentration – A Case Report

Pathology
Forensic MedicinePathology
2020English

Idarucizumab Dosing in Patients With Excessive Dabigatran Body Burden

British Journal of Anaesthesia
AnesthesiologyPain Medicine
2019English

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Case Reports in Cardiology
Cardiovascular MedicineCardiology
2017English

Immediate Reversal of Dabigatran by Idarucizumab Prior to Laboratory and Imaging Results in Acute Stroke

Frontiers in Neurology
Neurology
2019English

Adverse Clinical Outcomes After Dabigatran Reversal With Idarucizumab to Facilitate Acute Stroke Thrombolysis

Journal of Neurology
Neurology
2017English

Idarucizumab for Urgent Reversal of Dabigatran for Heart Transplant: A Case Report

American Journal of Hematology
Hematology
2017English

Midday Meals Do Not Impair Mouse Memory

Scientific Reports
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy